Phase I/II Trial of Pre-Operative Image Guided Intensity Modulated Proton Radiation Therapy (IMPT) or Photon (IMRT) with Simultaneously Integrated Boost to the High Margin for Retroperitoneal Sarcomas
The purpose of this study is to determine the highest dose of radiation therapy with protons or IMRT that can be delivered safely in patients with retroperitoneal sarcomas and the effectiveness of proton beam radiation therapy as an intervention for patients with retroperitoneal sarcomas.
Objectives: - For the Phase I portion of the study, to determine the maximum tolerated dose (MTD) of preoperative IG-IMPT and IMRT with simultaneously integrated boost to the high risk margin of retroperitoneal sarcoma. This is mainly based on evaluation of acute toxicity profile of each participant. - For the Phase II portion of the study, to determine the local control rate after the protocol treatment (IG-IMPT or IMRT MTD with simultaneously integrated boost to the high risk margin) followed by surgical resection.
Not Applicable (); Radiotherapy ()
- Inclusion Criteria:
- Histologically proven primary soft tissue sarcoma of the retroperitoneum
- Measurable disease
- Life expectancy of greater than 2 years
- Exclusion Criteria:
- Prior radiation therapy for retroperitoneal sarcoma
- Pregnant or breastfeeding
- Chemotherapy within 4 weeks prior to entering study
- Receiving other investigational agents
- Other types of sarcomas
- Multifocal disease, lymph node or distant metastases
- History of sensitivity to radiation therapy
- Uncontrolled intercurrent illness
- History of a different invasive malignancy within the past 3 years
- HIV positive on combination anti-retroviral therapy
If you are interested in learning more about clinical trials, our clinical trial navigators can discuss your options and recommend opportunities that may be suitable for you. Call 813-745-6100 or 1-800-679-0775 (toll-free) or submit a clinical trials inquiry form.